Molecular Imaging has entered into a licensing agreement with Dana-Farber Cancer Institute to access a substantial number of luciferase-enabled cancer cell lines developed at Dana-Farber. Access to these lines expands Molecular Imaging’s ability to apply bioluminescent imaging technology to a broad array of cancer disease models, including expanded capability in various leukemias, multiple myeloma, triple-negative breast cancer, glioma and melanoma.  

“This licensing relationship gives Molecular Imaging access to over 100 additional luc-enabled cell lines, providing the ability to use imaging in a much broader array of cancer disease models, with greater confidence.  Access to the knowledge and skills of Drs Kung and Armstrong only makes the opportunity to advance the science of imaging more compelling.  We look forward to collaborating with Andrew and Scott in making these cell lines available as part of our services to pharmaceutical and biotechnology companies to enhance R&D decision-making,” said W. R. Leopold, PhD, VP, research and development, at Molecular.

Molecular Imaging expects to nearly triple its validated luc-reporter cell line library by end of first quarter 2012.